Patent ID: 6177404
Filing Date: 2001-01-23
Classification: A61K

Abstract:
A method of treating benign prostatic hyperplasia which comprises administering to a mammal in need of said treatment a conjugate, said conjugate which comprises a cytotoxic agent attached to an oligopeptide, wherein the oligopeptide is a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen, wherein the means of attachment is directly through a covalent bond or via a linker unit, and wherein the cytotoxic agent is a member of a class of cytotoxic agents selected from the following classes:a) anthracycline family of drugs,b) the vinca alkaloid drugs,c) the mitomycins,d) the bleomycins,e) the cytotoxic nucleosides,f) the pteridine family of drugs,g) diynenes,h) estramustine,i) cyclophosphamide,j) the podophyllotoxins, andk) the taxanes;or a pharmaceutically acceptable salt thereof.